Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.
about
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Co-opting biology to deliver drugsDifferential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance.Spontaneous resolution of acute rejection and tolerance induction with IL-2 fusion protein in vascularized composite allotransplantation.
P2860
Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of an agonist interleu ...... urvival in non-human primates.
@en
Effects of an agonist interleu ...... urvival in non-human primates.
@nl
type
label
Effects of an agonist interleu ...... urvival in non-human primates.
@en
Effects of an agonist interleu ...... urvival in non-human primates.
@nl
prefLabel
Effects of an agonist interleu ...... urvival in non-human primates.
@en
Effects of an agonist interleu ...... urvival in non-human primates.
@nl
P2093
P2860
P1476
Effects of an agonist interleu ...... urvival in non-human primates.
@en
P2093
Gilles Benichou
Joren C Madsen
Maria Koulmanda
Ognjenka M Nadazdin
Svjetlan Boskovic
Terry B Strom
Timothy Millington
Xin Xiao Zheng
P2860
P304
P356
10.1016/J.HEALUN.2012.01.864
P577
2012-02-24T00:00:00Z